News >

Cabozantinib Active in Carcinoid Tumors and Pancreatic NETs

Angelica Welch
Published: Wednesday, Feb 07, 2018

Jennifer A. Chan, MD

Jennifer A. Chan, MD
Cabozantinib (Cabometyx) demonstrated promising clinical activity in patients with carcinoid tumors and pancreatic neuroendocrine tumors (NETs) in a phase II trial.

, Chan, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discussed the significance of the phase II results of cabozantinib in patients with carcinoid tumors and pancreatic NETs.

OncLive: Can you provide an overview of this trial?

Chan: We conducted a phase II trial of cabozantinib in patients with advanced carcinoid and pancreatic NETs. There have been a lot of recent advances in the treatment of NETs, but there is still an unmet need for patients whose disease has progressed on available therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x